Journey Medical Corporation

What they do

Journey Medical licenses or acquires rights to FDA-approved prescription dermatology products, funds their development where needed, and commercializes them through its own field sales organization. Its portfolio covers acne, rosacea, hyperhidrosis, fungal infections and wound care. The company is headquartered in Scottsdale, Arizona, and is majority-controlled by Fortress Biotech.

Revenue drivers

• Emrosi — Minocycline hydrochloride extended-release capsules 40 mg for inflammatory lesions of rosacea, FDA-approved November 2024, launched April 2025; generated $8.1 million in Q2 2026, roughly 44% of the quarter's $18.5 million total revenue.
• Qbrexza — Medicated cloth towelette for primary axillary hyperhidrosis in patients nine and older, acquired and launched May 2021; part of the branded patent-protected base the company says drives most revenue.
• Accutane, Amzeeq and Zilxi — Oral isotretinoin for severe recalcitrant nodular acne (licensed July 2020, launched March 2021), minocycline topical foam 4% for acne and 1.5% for rosacea (both acquired and launched January 2022); collectively the established branded dermatology base.
• Legacy products — Exelderm cream and solution, Targadox oral doxycycline and Luxamend wound-care emulsion; continued but smaller contributors alongside the eight-to-nine marketed FDA-approved drugs.

Recent performance

Q2 2026 total revenues were $18.5 million, up 23% from $15.0 million in Q2 2025, driven by Emrosi revenues of $8.1 million. Gross margin was 67%, consistent with the prior-year quarter, while SG&A fell $1.0 million year over year to $10.9 million on lower Emrosi launch spending. GAAP net loss narrowed to $0.3 million, or $(0.01) per share, from $3.8 million, or $(0.16) per share, a year earlier, and the company reported positive EBITDA and Adjusted EBITDA for both the three- and six-month periods. Emrosi total prescriptions were approximately 36,000 in Q2 2026 versus about 30,000 in Q1 2026 and 27,000 in Q4 2025. Cash and cash equivalents were $25.6 million at June 30, 2026, versus $24.1 million at December 31, 2025.

Strategy

The stated priority is commercializing Emrosi as a best-in-class oral rosacea treatment using the existing dermatology sales team, supported by growing prescription demand and payer coverage. The company describes disciplined cost management and continued investment in its dermatology commercial infrastructure as the path toward profitability. It also cites more than $25 million in cash as sufficient to execute on this strategy. Acquisition and in-licensing of additional FDA-approved dermatology products remains the stated model for building the portfolio.

Risks

• Dependence on Emrosi — The company's own risk disclosure ties the success of its business to commercializing Emrosi, and that single product supplied $8.1 million of Q2 2026's $18.5 million in revenue.
• Generic competition and loss of exclusivity — A substantial portion of sales comes from products that may face third-party generic competition because exclusivity has ended or they lack patent protection, which could significantly reduce operating income.
• Going concern doubt — The 10-Q risk factors list substantial doubt about the company's ability to continue as a going concern, alongside a potential need to raise additional capital.
• Parent control and concentration — Fortress Biotech controls a voting majority of the common stock, which the company says could be detrimental to other shareholders, and revenue depends mainly on a narrow set of dermatology products.

Outlook

Management says the 23% year-over-year revenue growth, expanding Emrosi prescription demand and payer coverage, and more than $25 million in cash leave the company well-positioned to execute its strategy and deliver strong financial performance. Stated direction is continued revenue growth with disciplined cost management toward profitability.